Early benefit assessments Archives — Page 6 of 9 — German Market Access

G-BA decisions from 19 October 2023

Here are the G-BA decisions from the G-BA meeting held on 19 October 2023 on the early benefit assessments of Hemgenix, Libtayo,

Here are the G-BA decisions from the G-BA meeting held on 5 October 2023 on the early benefit assessments of Imfinzi, Imjudo,

Here are the G-BA decisions from the G-BA meeting held on 21 September 2023 on the early benefit assessments of Nubeqa, Spravato,

Here are the G-BA decisions from the G-BA meeting held on 17 August 2023 on the early benefit assessments of Carvykti, Hemlibra,

Here are the G-BA decisions from the G-BA meeting held on 3 August 2023 on the early benefit assessments of Fintepla and

Here are the G-BA decisions from the G-BA meeting held on 20 July 2023 on the early benefit assessments of Enhertu, Imbruvica,

Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza

Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya,

Since 2020, the G-BA can request real-world evidence data collection in Germany. However, so far this was only implemented for one product,

Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,